Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This paper has been retracted. The record we hold marks it as a retracted publication. Check the original source below for the retraction notice before relying on anything it reports.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Retracted — do not rely on it alzhub usefulness score 16 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may modifiable by intervention with menatetrenone (vitamin K2) and risedronate sodium; we address the possibility that treatment with menatetrenone, risedronate and calcium may reduce the incidence of nonvertebral fractures in elderly patients with AD. A total of 231 elderly patients with AD were randomly assigned to daily treatment with 45 mg of menatetrenone or a placebo combined with once weekly risedronate sodium, and followed up for 12 months. At baseline, patients of both groups showed high undercarboxylated osteocalcin (ucOC) and low 25-OHD insufficiency with compensatory hyperparathyroidism. During the study period, BMD in the treatment group increased by 5.7% and increased by 2.1% in the control group. Nonvertebral fractures occurred in 15 patients (10 hip fractures) in the control group and 5 patients (2 hip fractures) in the treatment group. The relative risk in the treatment group compared with the control group was 0.31 (95% confidence interval, 0.12-0.81). Elderly AD patients with hypovitaminosis K and D are at increased risk for hip fracture. The study medications were well tolerated with relatively few adverse events and effective in reducing the risk of a fracture in elderly patients with AD.

What this study adds

Evidence grade: Low

This is a trial of 15 participants. In this trial of 231 elderly patients with Alzheimer's disease, treatment with menatetrenone, risedronate, and calcium reduced the relative risk of nonvertebral fractures, including hip fractures. Reported effect size: increased by 5.7%; increased by 2.1%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Sato, Y., Honda, Y., Umeno, K., Hayashida, N., Iwamoto, J., Takeda, T., et al. (2011). The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial. The Kurume medical journal. https://doi.org/10.2739/kurumemedj.57.117

Vancouver

Sato Y, Honda Y, Umeno K, Hayashida N, Iwamoto J, Takeda T, et al. The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial. The Kurume medical journal. 2011. doi:10.2739/kurumemedj.57.117. PMID: 21778673.

BibTeX

@article{sato2011-21778673,
  author  = {Sato, Y. and Honda, Y. and Umeno, K. and Hayashida, N. and Iwamoto, J. and Takeda, T. and Matsumoto, H.},
  title   = {{The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial}},
  journal = {The Kurume medical journal},
  year    = {2011},
  doi     = {10.2739/kurumemedj.57.117},
  pmid    = {21778673},
  url     = {https://doi.org/10.2739/kurumemedj.57.117}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

In this trial of 231 elderly patients with Alzheimer's disease, treatment with menatetrenone, risedronate, and calcium reduced the relative risk of nonvertebral fractures, including hip fractures. This treatment addresses fracture prevention in people with Alzheimer's disease, not the disease itself.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 11 of 12; Strength of evidence 1 of 5; Peer-review validation 0 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 2 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 29 of the 94 points it could be judged on, which is 31 of 100. Raw total 31 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 31 of 100capped at 16 — hatched points do not count

Retracted — do not rely on it. It scored 31 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. We have no data on impact for its field and year, so that was left out: it earned 29 of the 94 points we could judge it on, which is 31 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (The Kurume medical journal)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 0 / 10 Retracted — do not rely on it. PubMed indexes it as a Retracted Publication.
How recent 1 / 5 2011 — within 20 year(s) of the newest study here
Sample size 1 / 4 15 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 2 / 7 Cited 7 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.4 citations a year over 17 year(s) since 2011
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Hideo Matsumoto: h-index 18 (OpenAlex, whole career)
Institution's track record 1 / 3 Keio University: institution h-index 735 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 21778673)
Free to read 0 / 2 Behind a paywall — scores zero
Points 29 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 94 points we could judge it on is 31 out of 100.
Total 31 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →